Tumor endothelial up-regulation of IDO1 limits the response to CD40-stimulating immunotherapy
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA540971 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR9007040.fastq.gz | Fastqsanger.gz | |||
| SRR9007033.fastq.gz | Fastqsanger.gz | |||
| SRR9007034.fastq.gz | Fastqsanger.gz | |||
| SRR9007035.fastq.gz | Fastqsanger.gz | |||
| SRR9007036.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:CD40-stimulating immunotherapy elicits potent anti-tumor responses, which are mainly T-cell dependent. Here, we have investigated how tumor endothelial cells respond to CD40-stimulating immunotherapy by isolating endothelial cells from B16.F10 melanoma in anti-CD40 treated or isotype treated mice followed by RNA-sequencing. Gene set enrichment analysis revealed an increase in interferon- related responses in tumor endothelial cells following anti-CD40 therapy. The immunosuppressive enzyme indoleamine 2, 3-dioxygenase 1 (IDO1) was preferentially expressed in endothelial cells, and it was up-regulated upon anti-CD40 treatment. IDO1 expression in tumor endothelium was positively correlated to T-cell infiltration and to increased expression of IFNγ in the tumor microenvironment. In vitro, endothelial cells up-regulated IDO1 in response to T-cell-derived IFNγ, but not in response to CD40-stimulation. Combining agonistic anti-CD40 therapy with the IDO1 inhibitor epacadostat delayed tumor growth and increased survival in B16.F10 tumor-bearing mice, which was associated with increased activation of tumor-infiltrating T-cells. Hereby, we have uncovered an immunosuppressive feedback mechanism, in which tumor vessels limit the efficacy of cancer immunotherapy by up-regulating IDO1 in response to T-cell activation.
2020-04-06 | GSE130679 | GEO
Project description:The CD40 gene, an important immune regulatory gene, is also expressed and functional on non-myeloid derived cells, many of which are targets for tissue specific autoimmune diseases, including d thyroid follicular cells in Graves’ disease (GD). Whether target tissue CD40 expression plays a role in autoimmune disease etiology has yet to be determined. Here we show for the first time, that target-tissue over-expression of CD40 plays a key role in the etiology of autoimmunity. Using a murine model of GD, we demonstrated that thyroidal CD40 over-expression augmented the production of thyroid specific antibodies, resulting in more severe experimental autoimmune Graves’ disease (EAGD), whereas deletion of thyroidal CD40 suppressed disease. Using transcriptome and immune-pathway analyses we showed that in both EAGD mouse thyroids and human primary thyrocytes, CD40 mediates this effect by activating downstream cytokines and chemokines, most notably IL-6. To translate these findings into therapy, we blocked IL-6 during EAGD induction in the setting of thyroidal CD40 over-expression, and showed decreased levels of TSHR stimulating antibodies and frequency of disease. We conclude that target tissue over-expression of CD40 plays a key role in the etiology of organ specific autoimmune disease. CD40 in Thyroid Autoimmunity: 1) Incubation of human thyroid cells with G28.5, a CD40 stimulating antibody, and purification of RNA, conversion to cDNA, measurement of mRNA expression using RNAseq. 2) Removal of thyroid tissues from CD40 over-expressing transgenic mice and wild type mice, purification of RNA, conversion to cDNA measurement of mRNA expression using RNAseq.
2012-10-03 | E-GEOD-39081 | biostudies-arrayexpress
Project description:CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on tumor endothelial cells has not been evaluated. Here, we have investigated how tumor endothelial cells transcriptionally respond to CD40-stimulating immunotherapy by isolating tumor endothelial cells from agonistic CD40 mAb- or isotype-treated mice bearing B16-F10 melanoma, and performing RNA-sequencing. Gene set enrichment analysis revealed that agonistic CD40 mAb therapy increased interferon (IFN)-related responses in tumor endothelial cells, including up-regulation of the immunosuppressive enzyme Indoleamine 2, 3-Dioxygenase 1 (IDO1). IDO1 was predominantly expressed in endothelial cells within the tumor microenvironment, and its expression in tumor endothelium was positively correlated to T-cell infiltration and to increased intratumoral expression of IFNγ. In vitro, endothelial cells up-regulated IDO1 in response to T-cell-derived IFNγ, but not in response to CD40-stimulation. Combining agonistic CD40 mAb therapy with the IDO1 inhibitor epacadostat delayed tumor growth in B16-F10 melanoma, associated with increased activation of tumor-infiltrating T-cells. Hereby, we show that the tumor endothelial cells up-regulate IDO1 upon CD40-stimulating immunotherapy in response to increased IFNγ-secretion by T-cells, revealing a novel immunosuppressive feedback mechanism whereby tumor vessels limit T-cell activation.
| S-EPMC7094447 | biostudies-literature
Project description:Rattus norvegicus Cd40, CD40 molecule [Source:RGD Symbol;Acc:619830], is expressed in 4 baseline experiment(s);
| ENSRNOG00000018488 | ExpressionAtlas
Project description:Rattus norvegicus Cd40, CD40 molecule [Source:RGD Symbol;Acc:619830], is differentially expressed in 22 experiment(s);
| ENSRNOG00000018488 | ExpressionAtlas
Project description:Sus scrofa CD40, CD40 molecule [Source:VGNC Symbol;Acc:VGNC:95545], is differentially expressed in 3 experiment(s);
| ENSSSCG00000035078 | ExpressionAtlas
Project description:Macaca mulatta CD40, CD40 molecule [Source:VGNC Symbol;Acc:VGNC:70703], is expressed in 2 baseline experiment(s);
| ENSMMUG00000003683 | ExpressionAtlas
Project description:Homo sapiens CD40, CD40 molecule [Source:HGNC Symbol;Acc:HGNC:11919], is differentially expressed in 146 experiment(s);
| ENSG00000101017 | ExpressionAtlas
Project description:Homo sapiens CD40, CD40 molecule [Source:HGNC Symbol;Acc:HGNC:11919], is expressed in 39 baseline experiment(s);
| ENSG00000101017 | ExpressionAtlas
Project description:Sus scrofa CD40, CD40 molecule [Source:VGNC Symbol;Acc:VGNC:95545], is expressed in 3 baseline experiment(s);
| ENSSSCG00000035078 | ExpressionAtlas